Navigation Links
Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
Date:1/18/2013

to advance our rich pipeline of drug candidates."

Biscayne's lead GHRH antagonist is in preclinical development initially for the treatment of castrate-resistant prostate cancer (CRPC), a particularly lethal form of prostate cancer affecting 30,000 new patients each year in the US.  The GHRH antagonists work through a novel pathway that reduces the levels of hormones fueling the growth of tumors.  In animal studies, these antagonists have shown promising anti-tumor activity and were synergistic with chemotherapy.  The company believes that GHRH antagonists may have therapeutic potential in many other types of tumors, including breast, brain, lung, colon and skin.

Biscayne's lead GHRH agonists have demonstrated a unique capacity to repair the heart following ischemic injury, such as a heart attack, and are in preclinical development for the repair of damaged cardiac tissue.  GHRH agonists directly activate GHRH receptors in the heart, stimulating tissue healing through a variety of mechanisms.  GHRH agonists may represent a new class of therapy for cardiac conditions that presently afflict millions of patients worldwide.

In preclinical studies, GHRH agonists improved both cardiac structure and function and reduced myocardial infarct size and scarring, thereby reducing the chance of future heart failure.  Joshua M. Hare , MD, a scientific co-founder of Biscayne, who is the Louis Lemberg Professor of Medicine in the University of Miami Health System, is working with Dr. Schally to develop the GHRH technology for coronary heart disease.Dr. Hare noted, "Despite the many advances in cardiovascular therapy, millions of patients are disabled and ultimately killed each year from cardiac damage due to coronary heart disease.  Our GHRH agonists represent a unique and powerful approach aimed at developing drugs to reduce and repair this damage.  I look forward to working with the Biscayne
'/>"/>

SOURCE Biscayne Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
2. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
3. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
4. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
5. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
9. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... Calif. , Aug. 20, 2014 /PRNewswire-iReach/ -- ... the transformative collaboration between the school,s bioengineering department ... part of the Intel® Software Academic Program, UCSD,s ... sciences and the human body.  ... The study exhibits the work of Dr. ...
(Date:8/20/2014)... 2014 WriteResult®, a leading provider of ... has expanded its myPROpad™ ePRO tablet with the addition ... of the most widely used and well-respected Patient Reported ... The EQ-5D is used during clinical trials and in ... can be used to demonstrate Health-Related Quality of Life ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... (NYSE Amex: CUR ) announced that the ongoing ... in amyotrophic lateral sclerosis (ALS or Lou Gehrig,s disease) was ... http://www.neuralstem.com/neuralstem-in-the-news (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) The trial ... injections. About Neuralstem ...
... N.J., Nov. 13, 2011 Pharmasset, Inc. (Nasdaq: ... Capital Markets 8th Annual Healthcare Conference to be held November ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will provide ... 3:00 PM (ET). To access a simultaneous webcast ...
... Discharge 1-2-3 of Schaumburg, IL has been ... Innovation Awards for their Discharge 1-2-3 Composer™. The ... Theater on Tuesday, November 8, with more than 1400 people ... the Chicago region,s foremost recognition of the most innovative new ...
Cached Biology Technology:Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at the Lazard Capital Markets Healthcare Conference 3Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award 2Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award 3
(Date:8/20/2014)... State University, the Wellcome Trust Sanger Institute and the ... Mycobacterium pinnipedii from skeletons found in Peru ... is a relative of the TB bacterium that affects ... These researchers assume that seals carried the pathogens from ... lions was unexpected" comments Sebastien Gagneux, from the Swiss ...
(Date:8/20/2014)... Research UK scientists have discovered that acral melanomas the ... Marley,s death are genetically distinct from other more common ... external) published in the journal Pigment Cell & Melanoma ... of the hands, soles of the feet, nail-beds and other ... of melanoma, it,s not caused by UV damage from the ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2
... Leuven, Belgium - When a blood vessel clogs up, a ... die. However, working with mice, VIB scientists connected to the ... with severe hypoxia from dying. The muscles seem to adapt ... force that animals also use when hibernating, but that has ...
... critical difference between flu viruses that infect birds and humans, ... avian flu strains and aid in the development of vaccines ... a virus,s ability to infect humans depends on whether it ... surface of human respiratory cells. Now that we know ...
... in marine biomedical laboratories at Scripps Institution of Oceanography ... information about the fundamental biological processes inside a marine ... to treat cancer in humans. The finding could lead ... human diseases. A research team led by Bradley ...
Cached Biology News:Medical breakthrough for organ transplants and cardiovascular diseases by Flemish researchers 2MIT finds key to avian flu in humans 2MIT finds key to avian flu in humans 3Researchers uncover key trigger for potent cancer-fighting marine product 2
... Extraction Software reads and processes ... prepare microarray data for analysis. ... one 1-year license for ... accounts ,one CD-ROM containing Feature ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... handling system from Molecular Devices provides precise ... instrument. The system handles a variety of ... 384- and 1536-welland is the first to ... been optimized to dispense from four different ...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
Biology Products: